Assembly Biosciences Files 8-K

TL;DR

Assembly Bio filed a standard 8-K, no major news.

AI Summary

Assembly Biosciences, Inc. filed an 8-K on August 8, 2025, reporting on other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates routine corporate reporting by Assembly Biosciences, Inc. without disclosing specific material events or financial updates.

Risk Assessment

Risk Level: low — The filing is a routine 8-K with no disclosed material events, indicating no immediate new risks.

Key Players & Entities

• Assembly Biosciences, Inc. (company) — Registrant
• August 8, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 001-35005 (commission_file_number) — SEC File Number
• Two Tower Place, 7th Floor, South San Francisco, California 94080 (address) — Principal Executive Offices
• (833) 509-4583 (phone_number) — Registrant's Telephone Number

FAQ

From the Filing

0001193125-25-176138.txt : 20250808 0001193125-25-176138.hdr.sgml : 20250808 20250808082447 ACCESSION NUMBER: 0001193125-25-176138 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250808 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250808 DATE AS OF CHANGE: 20250808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 251196295 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 8-K 1 d802767d8k.htm 8-K 8-K false 0001426800 0001426800 2025-08-08 2025-08-08     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025     Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-35005   20-8729264 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   Two Tower Place , 7th Floor , South San Francisco , California   94080 (Address of Principal Executive Offices)   (Zip Code) Registrant’s Telephone Number, Including Area Code: (833) 509-4583 Not Applicable (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001   ASMB   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 7.01 Regulation FD Disclosure. On August 8, 2025, Assembly Biosciences, Inc. (the “Company”) issued a press release announcing interim results from the Phase 1b portion of its ongoing Phase 1a/b clinical study evaluating ABI-5366, an investigational long-acting herpes simplex virus (“HSV”) helicase-primase inhibitor candidate for recurrent genital herpes (the “ABI-5366 Study”). A copy of the press release is attached as Exhibit 99.1 and is i